The ARHGEF12 antibody targets the ARHGEF12 protein, encoded by the ARHGEF12 gene (HGNC: 19123), which belongs to the Rho guanine nucleotide exchange factor (RhoGEF) family. This protein, also termed Lsc, activates Rho GTPases by facilitating the exchange of GDP for GTP, thereby regulating cytoskeletal dynamics, cell migration, and polarity. ARHGEF12 contains a tandem Dbl homology (DH) and pleckstrin homology (PH) domain critical for its GEF activity and membrane association. It interacts with heterotrimeric G proteins, linking G protein-coupled receptor (GPCR) signaling to Rho-mediated pathways.
ARHGEF12 antibodies are essential tools in studying its expression, localization, and function in cellular processes. They are widely used in techniques like Western blotting, immunofluorescence, and immunohistochemistry to investigate ARHGEF12's role in physiological and pathological contexts. Dysregulation of ARHGEF12 has been implicated in cancers (e.g., hepatocellular carcinoma, glioblastoma) and neurological disorders, with studies suggesting its involvement in metastasis and neuronal development. Antibodies specific to ARHGEF12 help identify post-translational modifications, protein-protein interactions, and expression patterns across tissues. Commercial antibodies are typically validated for specificity using knockout controls or siRNA knockdown. Research utilizing these antibodies continues to elucidate ARHGEF12's contribution to disease mechanisms and potential therapeutic targets.